bioAffinity Technologies, Inc. (NASDAQ: BIAF) Stock Competitors & Peer Comparison
See BIAF's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BIAF and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BIAF | $6.83 | -13.87% | 3.1M | -0.87 | -$8.52 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.63% |
| TMO | $677.05 | +0.30% | 250.9B | 29.30 | $23.16 | +0.27% |
| DHR | $225.39 | +0.40% | 159.9B | 28.50 | $7.98 | +0.63% |
| NTRA | $412.24 | -0.08% | 59B | -311.95 | -$1.32 | N/A |
| A | $175.24 | +1.42% | 49.5B | 30.15 | $5.81 | +0.58% |
| IQV | $269.64 | -0.27% | 44.6B | 22.32 | $12.13 | N/A |
| WAT | $441.39 | +1.81% | 43.5B | 32.38 | $13.68 | N/A |
| IDXX | $533.53 | +2.75% | 41.7B | 37.21 | $14.22 | N/A |
| ILMN | $271.49 | +0.55% | 41.1B | 54.06 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BIAF vs DHR-PB Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BIAF's ROE is -2.57%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BIAF vs TMO Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, TMO has a market cap of 250.9B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while TMO trades at $677.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas TMO's P/E ratio is 29.30. In terms of profitability, BIAF's ROE is -2.57%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BIAF is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BIAF vs DHR Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, DHR has a market cap of 159.9B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while DHR trades at $225.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas DHR's P/E ratio is 28.50. In terms of profitability, BIAF's ROE is -2.57%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
BIAF vs NTRA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NTRA has a market cap of 59B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NTRA trades at $412.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NTRA's P/E ratio is -311.95. In terms of profitability, BIAF's ROE is -2.57%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, BIAF is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
BIAF vs A Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, A has a market cap of 49.5B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while A trades at $175.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas A's P/E ratio is 30.15. In terms of profitability, BIAF's ROE is -2.57%, compared to A's ROE of +0.20%. Regarding short-term risk, BIAF is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BIAF vs IQV Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, IQV has a market cap of 44.6B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while IQV trades at $269.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas IQV's P/E ratio is 22.32. In terms of profitability, BIAF's ROE is -2.57%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BIAF is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check IQV's competition here
Waters Corporation (NYSE: WAT)
BIAF vs WAT Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while WAT trades at $441.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas WAT's P/E ratio is 32.38. In terms of profitability, BIAF's ROE is -2.57%, compared to WAT's ROE of +0.02%. Regarding short-term risk, BIAF is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BIAF vs IDXX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while IDXX trades at $533.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas IDXX's P/E ratio is 37.21. In terms of profitability, BIAF's ROE is -2.57%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, BIAF is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
BIAF vs ILMN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ILMN has a market cap of 41.1B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ILMN trades at $271.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ILMN's P/E ratio is 54.06. In terms of profitability, BIAF's ROE is -2.57%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BIAF is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BIAF vs MTD Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MTD has a market cap of 31.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MTD trades at $1,530.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MTD's P/E ratio is 35.50. In terms of profitability, BIAF's ROE is -2.57%, compared to MTD's ROE of -12.00%. Regarding short-term risk, BIAF is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BIAF vs DGX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while DGX trades at $233.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas DGX's P/E ratio is 23.44. In terms of profitability, BIAF's ROE is -2.57%, compared to DGX's ROE of +0.14%. Regarding short-term risk, BIAF is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
BIAF vs LH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while LH trades at $308.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas LH's P/E ratio is 18.37. In terms of profitability, BIAF's ROE is -2.57%, compared to LH's ROE of +0.12%. Regarding short-term risk, BIAF is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
BIAF vs GH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, GH has a market cap of 23.8B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while GH trades at $176.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas GH's P/E ratio is -50.81. In terms of profitability, BIAF's ROE is -2.57%, compared to GH's ROE of +2.11%. Regarding short-term risk, BIAF is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BIAF vs EXAS Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BIAF's ROE is -2.57%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, BIAF is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BIAF vs MEDP Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MEDP has a market cap of 17.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MEDP trades at $619.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MEDP's P/E ratio is 36.10. In terms of profitability, BIAF's ROE is -2.57%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, BIAF is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BIAF vs ILMNV Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BIAF is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
BIAF vs RVTY Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, RVTY has a market cap of 16.8B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while RVTY trades at $151.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas RVTY's P/E ratio is 28.22. In terms of profitability, BIAF's ROE is -2.57%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, BIAF is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
BIAF vs PKI Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas PKI's P/E ratio is 41.45. In terms of profitability, BIAF's ROE is -2.57%, compared to PKI's ROE of +0.03%. Regarding short-term risk, BIAF is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BIAF vs CRL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CRL has a market cap of 14.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CRL trades at $294.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CRL's P/E ratio is 29.77. In terms of profitability, BIAF's ROE is -2.57%, compared to CRL's ROE of -0.08%. Regarding short-term risk, BIAF is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BIAF vs ICLR Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ICLR trades at $172.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ICLR's P/E ratio is 14.32. In terms of profitability, BIAF's ROE is -2.57%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, BIAF is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
BIAF vs QGEN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, QGEN has a market cap of 9.3B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while QGEN trades at $44.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas QGEN's P/E ratio is 18.60. In terms of profitability, BIAF's ROE is -2.57%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BIAF is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
BIAF vs GRAL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while GRAL trades at $135.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas GRAL's P/E ratio is -13.60. In terms of profitability, BIAF's ROE is -2.57%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BIAF is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
BIAF vs RDNT Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while RDNT trades at $70.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas RDNT's P/E ratio is 156.11. In terms of profitability, BIAF's ROE is -2.57%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BIAF is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BIAF vs BLLN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BLLN has a market cap of 5.6B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BLLN trades at $119.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BLLN's P/E ratio is 173.89. In terms of profitability, BIAF's ROE is -2.57%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
BIAF vs SHC Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while SHC trades at $18.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas SHC's P/E ratio is 19.22. In terms of profitability, BIAF's ROE is -2.57%, compared to SHC's ROE of +0.27%. Regarding short-term risk, BIAF is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BIAF vs SYNH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BIAF's ROE is -2.57%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BIAF vs VCYT Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while VCYT trades at $46.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas VCYT's P/E ratio is 22.62. In terms of profitability, BIAF's ROE is -2.57%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BIAF is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
BIAF vs CDNA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CDNA trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CDNA's P/E ratio is 76.90. In terms of profitability, BIAF's ROE is -2.57%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, BIAF is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BIAF vs OLK Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas OLK's P/E ratio is -96.59. In terms of profitability, BIAF's ROE is -2.57%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BIAF is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BIAF vs WGS Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while WGS trades at $77.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas WGS's P/E ratio is 238.69. In terms of profitability, BIAF's ROE is -2.57%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BIAF is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
BIAF vs PSNL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while PSNL trades at $16.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas PSNL's P/E ratio is -14.97. In terms of profitability, BIAF's ROE is -2.57%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, BIAF is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BIAF vs OPK Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas OPK's P/E ratio is -6.04. In terms of profitability, BIAF's ROE is -2.57%, compared to OPK's ROE of -0.06%. Regarding short-term risk, BIAF is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BIAF vs CSTL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CSTL trades at $34.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CSTL's P/E ratio is -54.44. In terms of profitability, BIAF's ROE is -2.57%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, BIAF is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BIAF vs FLGT Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, FLGT has a market cap of 635M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while FLGT trades at $22.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas FLGT's P/E ratio is 2236.00. In terms of profitability, BIAF's ROE is -2.57%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, BIAF is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BIAF vs GRALV Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas GRALV's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to GRALV's ROE of N/A. Regarding short-term risk, BIAF is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BIAF vs NEO Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NEO has a market cap of 495.7M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NEO trades at $18.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NEO's P/E ratio is 148.38. In terms of profitability, BIAF's ROE is -2.57%, compared to NEO's ROE of -0.06%. Regarding short-term risk, BIAF is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BIAF vs MYGN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MYGN has a market cap of 400.5M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MYGN trades at $4.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MYGN's P/E ratio is -32.62. In terms of profitability, BIAF's ROE is -2.57%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, BIAF is more volatile compared to MYGN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
BIAF vs CO Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CO's P/E ratio is 5.06. In terms of profitability, BIAF's ROE is -2.57%, compared to CO's ROE of +0.11%. Regarding short-term risk, BIAF is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BIAF vs FLDM Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BIAF's ROE is -2.57%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, BIAF is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BIAF vs BDSX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BDSX has a market cap of 247.6M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BDSX trades at $29.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BDSX's P/E ratio is -9.60. In terms of profitability, BIAF's ROE is -2.57%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, BIAF is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
BIAF vs XGN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while XGN trades at $8.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas XGN's P/E ratio is -10.47. In terms of profitability, BIAF's ROE is -2.57%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BIAF is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
BIAF vs FRNM Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, FRNM has a market cap of 132.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while FRNM trades at $15.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas FRNM's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to FRNM's ROE of N/A. Regarding short-term risk, BIAF is more volatile compared to FRNM. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BIAF vs GTH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas GTH's P/E ratio is -1.11. In terms of profitability, BIAF's ROE is -2.57%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BIAF is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BIAF vs GENE Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas GENE's P/E ratio is -38.25. In terms of profitability, BIAF's ROE is -2.57%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BIAF is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BIAF vs IMDX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, IMDX has a market cap of 102.7M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while IMDX trades at $3.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas IMDX's P/E ratio is -2.13. In terms of profitability, BIAF's ROE is -2.57%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BIAF is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
BIAF vs SERA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, SERA has a market cap of 77.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while SERA trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas SERA's P/E ratio is -3.11. In terms of profitability, BIAF's ROE is -2.57%, compared to SERA's ROE of -0.47%. Regarding short-term risk, BIAF is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
BIAF vs PRPO Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while PRPO trades at $23.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas PRPO's P/E ratio is -37.09. In terms of profitability, BIAF's ROE is -2.57%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BIAF is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BIAF vs QUCY Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, QUCY has a market cap of 31.2M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while QUCY trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas QUCY's P/E ratio is -0.06. In terms of profitability, BIAF's ROE is -2.57%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BIAF is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BIAF vs MDXH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MDXH has a market cap of 28.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MDXH trades at $0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MDXH's P/E ratio is -0.75. In terms of profitability, BIAF's ROE is -2.57%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BIAF is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
BIAF vs AKU Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas AKU's P/E ratio is -0.13. In terms of profitability, BIAF's ROE is -2.57%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BIAF is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BIAF vs BNR Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BNR has a market cap of 18.6M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BNR trades at $18.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BNR's P/E ratio is -20.26. In terms of profitability, BIAF's ROE is -2.57%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BIAF is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BIAF vs CEMI Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BIAF's ROE is -2.57%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BIAF is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BIAF vs ENZ Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BIAF's ROE is -2.57%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BIAF is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BIAF vs PMD Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas PMD's P/E ratio is -5.24. In terms of profitability, BIAF's ROE is -2.57%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BIAF is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BIAF vs ME Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ME's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -2.57%, compared to ME's ROE of -42.03%. Regarding short-term risk, BIAF is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BIAF vs MYNZ Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, BIAF's ROE is -2.57%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BIAF is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BIAF vs CHEK Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BIAF's ROE is -2.57%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BIAF is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BIAF vs BIAFW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BIAFW has a market cap of 9.8M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BIAFW trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BIAFW's P/E ratio is 1.04. In terms of profitability, BIAF's ROE is -2.57%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, BIAF is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
BIAF vs CNTG Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BIAF's ROE is -2.57%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BIAF is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BIAF vs ADVB Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ADVB trades at $6.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ADVB's P/E ratio is -61.18. In terms of profitability, BIAF's ROE is -2.57%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, BIAF is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BIAF vs NDRA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NDRA trades at $6.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NDRA's P/E ratio is -0.88. In terms of profitability, BIAF's ROE is -2.57%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BIAF is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BIAF vs APDN Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas APDN's P/E ratio is -0.10. In terms of profitability, BIAF's ROE is -2.57%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BIAF is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
BIAF vs NVTA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -2.57%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BIAF is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
BIAF vs LMDX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BIAF's ROE is -2.57%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BIAF is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BIAF vs LMDXW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -2.57%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BIAF is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check LMDXW's competition here
DermTech, Inc. (NASDAQ: DMTK)
BIAF vs DMTK Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BIAF's ROE is -2.57%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BIAF is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BIAF vs NOTV Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -2.57%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BIAF is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
BIAF vs SQL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas SQL's P/E ratio is -0.40. In terms of profitability, BIAF's ROE is -2.57%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BIAF is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BIAF vs AWH Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas AWH's P/E ratio is -0.09. In terms of profitability, BIAF's ROE is -2.57%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BIAF is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BIAF vs HTGM Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BIAF's ROE is -2.57%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BIAF is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BIAF vs BIOC Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BIAF's ROE is -2.57%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BIAF is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BIAF vs SQLLW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -2.57%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BIAF is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BIAF vs ISPC Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, ISPC has a market cap of 165.2K. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while ISPC trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas ISPC's P/E ratio is -0.04. In terms of profitability, BIAF's ROE is -2.57%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BIAF is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BIAF vs WGSWW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BIAF's ROE is -2.57%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BIAF is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BIAF vs OCDX Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BIAF's ROE is -2.57%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BIAF is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check OCDX's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BIAF vs CHEKZ Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BIAF is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check CHEKZ's competition here
Danaher Corporation (NYSE: DHR-PA)
BIAF vs DHR-PA Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BIAF's ROE is -2.57%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BIAF is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check DHR-PA's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BIAF vs MEUSW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, BIAF is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BIAF vs PRXL Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BIAF's ROE is -2.57%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BIAF is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BIAF.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BIAF vs NDRAW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BIAF is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check NDRAW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BIAF vs BNGOW Comparison September 2026
bioAffinity Technologies, Inc. (NASDAQ: BIAF) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BIAF stands at 3.1M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BIAF is priced at $6.83 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BIAF currently has a P/E ratio of -0.87, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BIAF's ROE is -2.57%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BIAF is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BIAF.Check BNGOW's competition here